AUROPHARMA.NS Aurobindo Pharma Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 484381 | 230798 | 47.65% |
| 2026-08-27 | 717677 | 415100 | 57.84% |
| 2026-08-26 | 679792 | 308460 | 45.38% |
| 2026-08-25 | 589518 | 301909 | 51.21% |
| 2026-08-24 | 969437 | 500274 | 51.60% |
| 2026-08-21 | 750168 | 460845 | 61.43% |
| 2026-08-20 | 805856 | 505754 | 62.76% |
| 2026-08-19 | 752484 | 439107 | 58.35% |
| 2026-08-18 | 573961 | 331581 | 57.77% |
| 2026-08-17 | 998350 | 424601 | 42.53% |
| 2026-08-14 | 824842 | 341542 | 41.41% |
| 2026-08-13 | 962633 | 505090 | 52.47% |
| 2026-08-12 | 796061 | 520343 | 65.36% |
| 2026-08-11 | 420527 | 202901 | 48.25% |
| 2026-08-10 | 1165336 | 602295 | 51.68% |
| 2026-08-07 | 2001257 | 804646 | 40.21% |
| 2026-08-06 | 1299019 | 407211 | 31.35% |
| 2026-08-05 | 1385223 | 656202 | 47.37% |
| 2026-08-04 | 2243122 | 1406275 | 62.69% |
| 2026-08-03 | 1496353 | 930962 | 62.22% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers AUROPHARMA.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 01 Apr 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge Revoke | Revokation of Pledge | 11635862 | 12668544753 | 33.51% | XBRL |
| 28 Mar 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge | Pledge Creation | 16700000 | 17585935000 | 33.51% | XBRL |
| 05 Mar 2024 | PAVANKUMAR PS | Employees/Designated Employees | Sell | Market Sale | 1000 | 1022000 | 0.00% | XBRL |
| 01 Mar 2024 | CHANDRASEKHAR REDDY KANDATI | Employees/Designated Employees | Sell | Market Sale | 2000 | 2094775 | 0.00% | XBRL |
| 26 Feb 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge Revoke | Revokation of Pledge | 10050000 | 10490190000 | 33.51% | XBRL |
| 26 Feb 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge Revoke | Revokation of Pledge | 2300000 | 2400740000 | 33.51% | XBRL |
| 16 Feb 2024 | S BALA SUBRAMANYAM REDDY | Employees/Designated Employees | Sell | Market Sale | 2000 | 2054000 | 0.00% | XBRL |
| 16 Feb 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge | Pledge Creation | 13400000 | 13347740000 | 33.51% | XBRL |
| 16 Feb 2024 | GITA RAO | Employees/Designated Employees | Sell | Market Sale | 1300 | 1277900 | 0.00% | XBRL |
| 16 Feb 2024 | K BHARATHI | Other | Sell | Market Sale | 35000 | 35598850 | 0.00% | XBRL |
| 16 Feb 2024 | ROOPAK SAWHNEY | Employees/Designated Employees | Sell | Market Sale | 3880 | 3923040 | 0.00% | XBRL |
| 19 Jan 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge | Pledge Creation | 250000 | 279712500 | 33.51% | XBRL |
| 19 Jan 2024 | RPR SONS ADVISORS PVT.LTD., P.SUNEELA RANI (Jointly holding) | Promoter Group | Pledge Revoke | Revokation of Pledge | 400000 | 449920000 | 33.51% | XBRL |
| 02 Jan 2024 | K R VIJAYAPAL REDDY | Employees/Designated Employees | Sell | Market Sale | 1000 | 1082600 | 0.00% | XBRL |
| 29 Dec 2023 | S SADANANDA REDDY | Other | Sell | Market Sale | 15000 | 16074150 | 0.04% | XBRL |
| 29 Dec 2023 | Akkiraju Venkata Satya Murali Mohan | Employees/Designated Employees | Sell | Market Sale | 4000 | 4310000 | 0.00% | XBRL |
| 29 Dec 2023 | P. SASHI KUMARAN | Employees/Designated Employees | Sell | Market Sale | 9000 | 9720146 | 0.00% | XBRL |
| 29 Dec 2023 | S Bala Subramanyam Reddy | Employees/Designated Employees | Sell | Market Sale | 1000 | 1079000 | 0.00% | XBRL |
| 27 Dec 2023 | GOUTAM SEN | Employees/Designated Employees | Sell | Market Sale | 1500 | 1598500 | 0.00% | XBRL |
| 27 Dec 2023 | Dr AMBATI RAMA MOHANA RAO | Employees/Designated Employees | Sell | Market Sale | 2500 | 2712500 | 0.03% | XBRL |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers AUROPHARMA.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
No persistent gap detected
Net Profit CAGR 22.05% vs CFO CAGR 32.29% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit +0.54% vs CFO +40.81%
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,580.15 Cr. | ₹7,567.02 Cr. | ₹7,796.07 Cr. | ₹7,978.52 Cr. | ₹8,382.12 Cr. | ₹7,868.14 Cr. | ₹8,285.70 Cr. | ₹8,645.90 Cr. | ₹8,853.34 Cr. | ₹9,150.35 Cr. | RevenueFromOperations |
| Net Profit | ₹908.75 Cr. incl. minority ₹907.35 Cr. | ₹919.22 Cr. incl. minority ₹918.22 Cr. | ₹817.38 Cr. incl. minority ₹816.95 Cr. | ₹854.81 Cr. incl. minority ₹845.57 Cr. | ₹903.47 Cr. incl. minority ₹902.83 Cr. | ₹824.75 Cr. incl. minority ₹824.20 Cr. | ₹848.45 Cr. incl. minority ₹848.13 Cr. | ₹910.29 Cr. incl. minority ₹909.80 Cr. | ₹921.26 Cr. incl. minority ₹920.84 Cr. | ₹1,032.56 Cr. incl. minority ₹1,032.03 Cr. | ProfitOrLossAttributableToOwnersOfParent |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers AUROPHARMA.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitOrLossAttributableToOwnersOfParent | 35047500000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 580800000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 327087500000.0 |
| CurrentLiabilities | 180390100000.0 |
| EquityAttributableToOwnersOfParent | 378909700000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | 76762000000.0 |